# Efficacy and Safety of Xeligekimab in the Treatment of Non-Radiographic Axial Spondyloarthritis

> **NCT07339566** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Lingli Dong** · enrollment: 40 (estimated)

## Conditions studied

- Nr-axial Spondyloarthritis
- Non-Radiographical Axial Spondyloarthritis

## Interventions

- **DRUG:** Xeligekimab injection

## Key facts

- **NCT ID:** NCT07339566
- **Lead sponsor:** Lingli Dong
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-31
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-01-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07339566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07339566, "Efficacy and Safety of Xeligekimab in the Treatment of Non-Radiographic Axial Spondyloarthritis". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT07339566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*